Beckman walks away from Biosite

Article Excerpt

BECKMAN COULTER INC. $68 (New York symbol BEC; Conservative Growth Portfolio, Manufacturing & Industry sector; Shares outstanding: 61.9 million; Market cap: $4.2 billion; WSSF Rating: Average) recently agreed to pay $85 a share (total $1.55 billion) for publicly traded Biosite Inc., which makes heart disease testing equipment. However, a rival bid forced Beckman to increase its offer to $90 a share ($1.67 billion). Biosite’s products generate higher profit margins than Beckman’s substance detection systems, which helped justify the higher offer. Biosite has now received a $92.50-a-share offer, and Beckman has refused to match it. Under the terms of its original agreement, Biosite will have to pay Beckman a $54 million termination fee. To put that in context, Beckman earned $0.59 a share (total $37.1 million) in the first quarter of 2007. Even without Biosite, we still like Beckman’s long-term prospects. The company dominates its niche markets, and its high research spending (around 9% of its revenue of $40 a share) makes it look…